Navigation Links
ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
Date:10/27/2011

ddress until November 18, 2011.

About ViroPharma Incorporated ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, Friedreich's Ataxia (FA), adrenal insufficiency and C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE) and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2011, our ability to successfully commercialize Cinryze and Buccolam in the EU, our ability to complete manufa
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
3. ViroPharma Announces Additional Securities Repurchase Program
4. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
5. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
6. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
7. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
8. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
9. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
10. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
11. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen ... the White House today for National Recovery Month, stars ... consumer advocates released today. Consumer advocates were also joined ... who spoke out after losing her fiancée because of ... the doctor had a history of crack cocaine abuse. ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire-iReach/ -- ChemImage announced ... discussing improvements in the development of imaging ... both normal and diseased tissue that minimizes ... surgical procedures, lowers surgical costs and potentially ... The clinical and scientific ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... 4 Novartis Vaccines & Diagnostics Inc. and Novartis ... to resolve civil False Claims Act allegations arising from the ... announced today. The settlement resolves allegations that, between Jan. ... and its predecessor, Chiron Corporation, caused false claims to be ...
... Joseph F. Finn, Jr. , C.P.A. ("Finn"),  Assignee for ... that the MRI imaging intellectual properties of the EP-3600 MRI imaging ... assets of Epix were transferred to him on July 20, ... Epix creditors.  He recently reached an agreement with Bayer Schering Pharma ...
Cached Medicine Technology:Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 2Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 3Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent 2
(Date:9/17/2014)... Dallas, TX (PRWEB) September 17, 2014 ... they were recently granted several awards for their top-notch ... regarding patient experience, orthopedic care and GYN surgery. , ... Patient Safety Excellence Award™. They have received this award ... ranked among the top 5 percent in the nation ...
(Date:9/17/2014)... News, VA (PRWEB) September 17, 2014 ... will host recruit757’s scholarship workshop for football players ... on Tuesday, Sept. 23. , Doors open at 6:30 ... Performance Center and speak to trainers and physical therapists. ... until 9 p.m. , The Newport News Tidewater Performance ...
(Date:9/17/2014)... messages about the health benefits of quitting smoking may ... suggests. Although smokers who think quitting will be ... effects of smoking, researchers found smokers who believe they ... or positive, messages about how quitting will improve their ... of both types of messages might get more people ...
(Date:9/17/2014)... September 17, 2014 Prevention is the ... is hospitalizing scores of infants, children and teenagers in ... Kirk Mahon, medical director of Legacy ER & Urgent ... been no reported cases of EV-D68 so far in ... that could change,” he said. “Implementing prevention strategies now ...
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... News) -- Body-building and weight-loss products are the types of ... a small new study. Liver injury from medication is ... and herbal supplements -- which do not require a prescription ... are used by up to 40 percent of people in ...
... (ICUs) that have no or limited access to critical care ... the specialists, called intensivists, staff the unit at night, according ... Pittsburgh School of Medicine and UPMC. However, the researchers were ... ICUs that were robustly staffed with the specialists during the ...
... Va. (May 22, 2012) The Food and Drug Administration ... group of rare cell disorders. The test, or assay, was ... field of mast cells. Lawrence Schwartz, M.D., Ph.D., chair ... Charles and Evelyn Thomas Professor of Medicine at VCU, has ...
... , TUESDAY, May 22 (HealthDay News) -- Got hair? If ... cancer, a preliminary study suggests. Researchers are reporting ... more likely to have cancer than were those with more ... that they may benefit from being screened earlier and perhaps, ...
... are not effective in determining which asthma patients are ... (ICS) medications without risk of flare-ups or exacerbations, according ... United Kingdom. The study also showed that nearly three-quarters ... use of ICS medications once their symptoms are under ...
... The new blood thinner Xarelto appears to lower the chances ... U.S. Food and Drug Administration review has found. The ... advance of an FDA advisory panel meeting Wednesday, at which ... of Xarelto for treating people with acute coronary syndrome (a ...
Cached Medicine News:Health News:Body Building, Diet Supplements Linked to Liver Damage: Study 2Health News:Intensivists at night improve patient outcomes in some ICUs, says Pitt/UPMC team 2Health News:FDA clears test developed in partnership with VCU researcher 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 3Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 2Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 3Health News:New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: